Imran Dosani, MD
Nephrology · Lawrenceville, GANPI 1215142401
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.7%), speaking fees and education — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Vifor Pharma, Inc. at 32.5% of the total. Reporting peaked in 2021 at $239 and has fallen 82.5% since, to $42 in 2024. That places this record below the midpoint for nephrology clinicians in GA, where the typical reported total is $1,554.
Across 16 payments — averaging $39.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$206
- AstraZeneca$137
- Otsuka America Pharmaceutical, Inc.$119
- Fresenius USA Marketing, Inc.$41
- Lundbeck LLC$40
- Amgen$34
- plus $57 from 2 others
What the payments were for
- Speaking & faculty fees$20032%
- Food & beverage$30248%
- Education$13221%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 2 | $206 |
| AstraZeneca | 3 | $137 |
| Otsuka America Pharmaceutical, Inc. | 4 | $119 |
| Fresenius USA Marketing, Inc. | 2 | $41 |
| Lundbeck LLC | 1 | $40 |
| Amgen | 1 | $34 |
| Bayer | 2 | $32 |
| Akebia Therapeutics Inc | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$634 in reported general payments places this provider in the 30th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 25 | $497,075 |
| XphozahTenapanor Hcl | 16 | $85,851 |
| KerendiaFinerenone | 85 | $58,543 |
| AuryxiaFerric Citrate | 32 | $47,025 |
| VeltassaPatiromer Calcium Sorbitex | 13 | $25,189 |
| LokelmaSodium Zirconium Cyclosilicate | 34 | $24,161 |
| InvokanaCanagliflozin | 30 | $22,956 |
| EntrestoSacubitril/Valsartan | 15 | $19,402 |
| Sevelamer Carbonate | 156 | $17,881 |
| FarxigaDapagliflozin Propanediol | 24 | $17,721 |
| Lanthanum Carbonate | 14 | $17,317 |
| Cinacalcet Hcl | 57 | $14,459 |
| JardianceEmpagliflozin | 15 | $12,843 |
| SpsSodium Polystyrene Sulfon/Sorb | 21 | $4,332 |
| Calcium Acetate | 39 | $3,286 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $119 | $497,07525 claims |
| BayerKerendia | $32 | $58,54385 claims |
| Akebia Therapeutics IncAuryxia | $25 | $47,02532 claims |
| AstraZenecaLokelma, Farxiga | $137 | $41,88158 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 388 nephrology providers in Georgia.
Other nephrology in Lawrenceville
- James TumlinLawrenceville$434K
- William PaxtonLawrenceville$73K
- Sharad VirmaniLawrenceville$55K
- Lorin SanchezLawrenceville$23K
- Aakash AminLawrenceville$22K
- Kathryn ElmoreLawrenceville$12K
- Shaun ConlonLawrenceville$11K
- Nnamdi NwaohiriLawrenceville$11K
- Jusong ChoiLawrenceville$8K
- Sagar PanseMacon$542K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.